A Randomized, Double Blind, Placebo-Controlled Phase III Study To Determine The Efficacy Of Sandostatin LAR® Depot (Octreotide Acetate) In Preventing Or Reducing The Severity Of Chemoradiation-Induced Diarrhea In Patients With Anal Or Rectal Cancer
A Randomized, Double Blind, Placebo-Controlled Phase III Study To Determine The Efficacy Of Sandostatin LAR® Depot (Octreotide Acetate) In Preventing Or Reducing The Severity Of Chemoradiation-Induced Diarrhea In Patients With Anal Or Rectal Cancer
RATIONALE: Octreotide may be effective in preventing or controlling diarrhea in patients who are undergoing chemoradiotherapy for anal or rectal cancer. It is not yet known whether octreotide is effective in treating diarrhea.
PURPOSE: This randomized phase III trial is studying octreotide in preventing or reducing diarrhea in patients who are undergoing chemoradiotherapy for anal or rectal cancer.
OBJECTIVES:
Primary
Secondary
OUTLINE: This is a double-blind, placebo-controlled, randomized, multicenter study. Patients are stratified according to radiotherapy dose (< 50 Gy vs ≥ 50 Gy), chemotherapy dose (bolus vs continuous), and gender. Patients are randomized to 1 of 2 treatment arms.
NOTE: *Patients receive a total of 2 injections of octreotide or placebo
In both arms, treatment continues in the absence of unacceptable toxicity.
Quality of life is assessed at baseline, at the completion of chemoradiotherapy, and at 3, 6, 9, and 15 months from the start of chemoradiotherapy.
Patients are followed at 3, 6, 9, and 15 months from the start of chemoradiotherapy.
PROJECTED ACCRUAL: A total of 226 patients (113 per treatment arm) will be accrued for this study within 2 years.
DISEASE CHARACTERISTICS:
Histologically confirmed primary anal or rectal cancer
Must be scheduled to receive chemoradiotherapy
PATIENT CHARACTERISTICS:
Age
Performance status
Life expectancy
Hematopoietic
Hepatic
Renal
Gastrointestinal
Other
PRIOR CONCURRENT THERAPY:
Biologic therapy
Chemotherapy
Endocrine therapy
At least 6 months since prior administration of any of the following:
Radiotherapy
Surgery
Other
Inglewood, California 90301, United States
Northridge, California 91328, United States
Sacramento, California 95815, United States
Grand Junction, Colorado 81502, United States
Fort Lauderdale, Florida 33308, United States
Tampa, Florida 33612-9497, United States
Lexington, Kentucky 40536-0084, United States
Baltimore, Maryland 21201, United States
Ann Arbor, Michigan 48106-0995, United States
Lebanon, New Hampshire 03756-0002, United States
Camden, New Jersey 08103, United States
Toms River, New Jersey 08755, United States
Rochester, New York 14621, United States
Salem, Ohio 44460, United States
Portland, Oregon 97210, United States
Portland, Oregon 97213-2967, United States
Drexel Hill, Pennsylvania 19026, United States
Hershey, Pennsylvania 17033-0850, United States
Pittsburgh, Pennsylvania 15224-1791, United States
Yakima, Washington 98902, United States
Milwaukee, Wisconsin 53215, United States